Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) saw a large drop in short interest during the month of July. As of July 31st, there was short interest totalling 1,150,000 shares, a drop of 8.0% from the July 15th total of 1,250,000 shares. Based on an average daily volume of 246,500 shares, the days-to-cover ratio is currently 4.7 days.
Corvus Pharmaceuticals Trading Up 7.9 %
Shares of NASDAQ:CRVS opened at $4.10 on Monday. The firm’s 50 day moving average is $2.39 and its two-hundred day moving average is $2.11. The firm has a market capitalization of $256.46 million, a P/E ratio of -7.88 and a beta of 1.11. Corvus Pharmaceuticals has a 52 week low of $1.05 and a 52 week high of $4.10.
Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.05. During the same quarter last year, the firm posted ($0.14) EPS. Analysts predict that Corvus Pharmaceuticals will post -0.49 EPS for the current year.
Analysts Set New Price Targets
View Our Latest Analysis on CRVS
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of CRVS. Cubist Systematic Strategies LLC acquired a new position in Corvus Pharmaceuticals during the second quarter valued at $44,000. Marshall Wace LLP acquired a new position in shares of Corvus Pharmaceuticals in the second quarter worth $136,000. Samlyn Capital LLC raised its holdings in shares of Corvus Pharmaceuticals by 160.7% during the second quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock worth $11,144,000 after acquiring an additional 3,774,658 shares in the last quarter. Towerview LLC boosted its position in Corvus Pharmaceuticals by 4.6% during the second quarter. Towerview LLC now owns 400,000 shares of the company’s stock valued at $728,000 after purchasing an additional 17,500 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Corvus Pharmaceuticals by 10.6% in the 1st quarter. Vanguard Group Inc. now owns 1,493,357 shares of the company’s stock valued at $2,658,000 after buying an additional 142,724 shares in the last quarter. Institutional investors own 46.64% of the company’s stock.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.
See Also
- Five stocks we like better than Corvus Pharmaceuticals
- EV Stocks and How to Profit from Them
- This Small Cap Wealth Management Stock Could Provide Big Returns
- How to Calculate Options Profits
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Are Penny Stocks a Good Fit for Your Portfolio?
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.